Why the study?
Special populations with chronic bleeding disorders, implant allergies, or chronic infections face increased risks of complications during neuromodulation therapies, creating a need for clinical guidance to ensure patient safety and optimal outcomes.
What are the best practices for spinal cord stimulation implantation in special patient populations to improve safety and efficacy?
What are the best practices for spinal cord stimulation implantation in special patient populations to improve safety and efficacy?
The American Society of Pain and Neuroscience provides best practice guidelines for spinal cord stimulation in special populations, noting that evidence in these groups is relatively modest and relies heavily on expert consensus.
Answers are grounded in this paper and cite their sources.
Expert guidance addresses neuromodulation risks in high-risk patients; leaves open prospective validation of safety protocols.
Chronic bleeding disorders, allergy to implants, and chronic infections are all complicating factors when considering neuromodulation therapies. The American Society of Pain and Neuroscience (ASPN) determined a need for clinical guidance in these special patient populations that have increased risk of complications, in order to ensure patient safety and optimal outcomes with device implantation. The purpose of this publication was to review the published literature and explore the unique clinical challenges encountered among several special patient populations with relation to spinal cord stimulation. The executive board of the ASPN appointed a diverse group of well-established physicians to develop best practice guidelines regarding spinal cord stimulation implantation in these special populations. The physicians used the United States Preventive Services Task Force (USPSTF) structured guidelines for grading and level of certainty to make evidence-based recommendations about clinical practice. Where sufficient evidence was lacking to justify a USPSTF ranking, the physicians queried experts in neuromodulation and achieved consensus. These best practices and interventional guideline found the evidence for the use of neuromodulation in specialized patient populations to be relatively modest.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted a review in Special patient populations (chronic bleeding disorders, allergy to implants, and chronic infections) considering neuromodulation therapies. Spinal cord stimulation was evaluated. Evidence for the use of spinal cord stimulation in specialized patient populations with chronic bleeding disorders, allergies, or infections was found to be relatively modest.
Synapse has enriched 10 related papers. Consider them for comparative context: